| escitalopram / Generic mfg. |
ACTRN12623000227695: The SAD-AF trial: a study of escitalopram (a selective serotonin reuptake inhibitor, SSRI) antidepressant vs placebo in patients with atrial fibrillation (AF) and depression, on AF-related quality of life |
|
|
| Not yet recruiting | 3 | 154 | | | Melbourne Health, Melbourne Health | atrial fibrillation, major depressive disorder | | | | |
2006-001491-21: Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning |
|
|
| Ongoing | 3 | 58 | Europe | Film-coated tablet, Cipralex 10 mg Filmtabletten | Max Planck Institute of Psychiatry | Effects on sleep electroencephalogram and motoric learning in healthy volunteers related to the permeability of the blood-brain-barrier related to genotypes of the ABCB 1 gene | | | | |
NCT00051259: Effects of Antidepressants on Sexual Functioning |
|
|
| Completed | 3 | 420 | US | Extended-Release Bupropion Hydrochloride | GlaxoSmithKline | Major Depressive Disorder (MDD) | 06/04 | 06/04 | | |
NCT00051272: Effects Of Antidepressants On Sexual Functioning In Adults |
|
|
| Completed | 3 | 425 | US | Extended-release Bupropion Hydrochloride | GlaxoSmithKline | Major Depressive Disorder (MDD) | 06/04 | 06/04 | | |
NCT00179257: The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram |
|
|
| Completed | 3 | 20 | US | sertraline (Zoloft) | Vanderbilt University, Pfizer | Major Depressive Disorder | | 03/05 | | |
NCT00073411: Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression |
|
|
| Completed | 3 | 675 | US | duloxetine, escitalopram, placebo | Eli Lilly and Company | Depression | | 05/05 | | |
NCT00148447: The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia |
|
|
| Completed | 3 | 40 | RoW | escitalopram | BeerYaakov Mental Health Center, Lundbeck Israel | Schizophrenia | | 09/05 | | |
NCT00109044: Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 540 | US | Escitalopram | Forest Laboratories | Major Depressive Disorder | 05/06 | 05/06 | | |
NCT00108979: Study of Escitalopram in Adult Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 240 | US | Escitalopram | Forest Laboratories | Major Depressive Disorder | 07/06 | 07/06 | | |
NCT00305500: Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD) |
|
|
| Completed | 3 | 100 | RoW | escitalopram | Abarbanel Mental Health Center | Obsessive-Compulsive Disorder | | 12/06 | | |
| Completed | 3 | 468 | US, Canada | SR58611A | Sanofi | Major Depressive Disorder | 01/07 | 05/07 | | |
| Completed | 3 | 476 | US, Canada | SR58611A | Sanofi | Major Depressive Disorder | 01/07 | 01/07 | | |
LIBRA, NCT00252343: Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder |
|
|
| Completed | 3 | 360 | US | SR58611A | Sanofi | Anxiety Disorder | 02/07 | 02/07 | | |
| Completed | 3 | 494 | Canada, Europe, RoW | Quetiapine, Amitriptyline, Bupropion, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine | AstraZeneca | Major Depressive Disorder | | 04/07 | | |
NCT00107120: The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 312 | US | Escitalopram, Lexapro (TM), Placebo | Forest Laboratories | Major Depressive Disorder | 05/07 | | | |
NCT00610506: Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features |
|
|
| Completed | 3 | 15 | US | Escitalopram, Escitalopram (Lexapro) | Duke University, Forest Laboratories | Atypical Depression | 05/07 | 05/07 | | |
NCT00114374: SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims |
|
|
| Terminated | 3 | 60 | US | Escitalopram | Massachusetts General Hospital | Anxiety Disorder | | 06/07 | | |
| Completed | 3 | 450 | Canada, Europe, RoW | Quetiapine SR, Escitalopram | AstraZeneca | Major Depressive Disorder | | 06/07 | | |
GOLD, NCT00329446: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder |
|
|
| Completed | 3 | 800 | US | Quetiapine Fumarate, Escitalopram oxylate | AstraZeneca | Generalized Anxiety Disorder | | 09/07 | | |
NCT00390650: A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder |
|
|
| Completed | 3 | 366 | US, Canada | Saredutant | Sanofi | Anxiety | 11/07 | 11/07 | | |
NCT00415142 / 2006-003793-94: An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 393 | US, Europe, RoW | saredutant (SR48968), placebo, escitalopram | Sanofi | Depressive Disorder | 02/08 | 02/08 | | |
NCT00406640: Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women |
|
|
| Completed | 3 | 595 | US, RoW | Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram | Wyeth is now a wholly owned subsidiary of Pfizer | Depression, Depressive Disorder, Depressive Disorder, Major | 02/08 | 10/08 | | |
| Completed | 3 | 510 | Europe, RoW | SR58611A, escitalopram, placebo | Sanofi | Major Depressive Disorder | 02/08 | 02/08 | | |
NCT00417118 / 2006-003805-19: An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder |
|
|
| Completed | 3 | 365 | Canada, Europe, RoW | Saredutant, Escitalopram, Placebo | Sanofi | Generalized Anxiety | 04/08 | 04/08 | | |
CIPPAD, NCT00136318: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients |
|
|
| Completed | 3 | 208 | Europe | Escitalopram, Placebo, Peginterferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin | Charite University, Berlin, Germany | Depression | 09/08 | 09/08 | | |
NCT00190333: Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension |
|
|
| Completed | 3 | 30 | Europe | escitalopram | Assistance Publique - Hôpitaux de Paris | Pulmonary Hypertension | 12/08 | 12/08 | | |
NCT00361218: Biological Markers of Response to Treatment in Major Depressive Disorder |
|
|
| Completed | 3 | 72 | NA | open-label selective serotonin reuptake inhibitor (SSRI), escitalopram or citalopram | Massachusetts General Hospital | Major Depressive Disorder | 12/08 | 12/08 | | |
| Completed | 3 | 643 | US, Europe, RoW | saredutant (SR48968), escitalopram, placebo | Sanofi | Major Depressive Disorder | 01/09 | 01/09 | | |
NCT00668525: Escitalopram in Adult Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 877 | US | Escitalopram, Placebo | Forest Laboratories | Major Depressive Disorder | 02/09 | | | |
2008-004182-26: Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression |
|
|
| Ongoing | 3 | 50 | Europe | Escitalopram, Lithiumcarbonat, Capsule, hard | Charité - Universitätsmedizin Berlin | 30-40% of depressed patients do not respond to the first course of drug treatment chosen. Over 50% of nonresponders to the first treatment also do not respond to a second, different treatment . Of those who do respond to the initial antidepressant, up to 50% do not reach full remission but rather display residual symptoms. Therefore, treatment optimization strategies should be considered at critical decision points early in the treatment progress to avoid prolonged treatment-resistant courses. | | | | |
NCT00296933: Memory Functioning and Antidepressant Treatment |
|
|
| Completed | 3 | 60 | Canada | Escitalopram, Bupropion XL | University Health Network, Toronto, GlaxoSmithKline, H. Lundbeck A/S | Depression, Major Depressive Disorder | | | | |
NCT00935675: Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment |
|
|
| Unknown status | 3 | 100 | Europe | Escitalopram | Gustave Roussy, Cancer Campus, Grand Paris | Carcinomas | | | | |
| Completed | 3 | 147 | US | escitalopram, placebo | Butler Hospital | Opiate Dependence, Depression | 09/09 | 09/09 | | |
NCT00887679: Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS |
|
|
| Completed | 3 | 30 | US | Escitalopram | Duke University, Forest Laboratories | Anxiety Disorders, HIV Infections | 09/09 | 09/10 | | |
NCT00074815: Treatment of Obsessive Compulsive Disorder in Children |
|
|
| Completed | 3 | 124 | US | Serotonin reuptake inhibitors management, Drug Name with Minimum-Maximum Dosage, Citalopram (Celexa)10-60;, Escitalopram (Lexapro)5-30;, Fluoxetine (Prozac) 10-60;, Fluvoxamine (Luvox)25-300;, Paroxetine (Paxil)10-50;, Paroxetine-CR (Paxil)10-50;, Clomipramine (Anafranil)25-200;, Sertraline (Zoloft) 25-200;, Venlafaxine (Effexor)25-225;, Venlafaxine XR (Effexor)37.5-225;, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist | Duke University, National Institute of Mental Health (NIMH) | Obsessive-Compulsive Disorder | 11/09 | 11/09 | | |
NCT00965497: Escitalopram (Lexapro) for Depression MS or ALS |
|
|
| Completed | 3 | 13 | US | escitalopram, Lexapro | University of South Carolina | Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis | 03/10 | 03/10 | | |
| Unknown status | 3 | 60 | Europe | CBASP psychotherapy, Escitalopram | University Hospital Freiburg, University Hospital, Bonn | Chronic Depression | 04/10 | 04/11 | | |
| Terminated | 3 | 29 | US | Escitalopram, Lexapro (escitalopram), Ramelteon, Rozerem (Ramelteon), Placebo | University of Texas Southwestern Medical Center, Takeda Pharmaceuticals North America, Inc. | Major Depressive Disorder, Insomnia | 05/10 | 05/10 | | |
NCT00387348: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer |
|
|
| Terminated | 3 | 24 | US | escitalopram oxalate, Placebo | Massachusetts General Hospital, National Cancer Institute (NCI) | Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer | 04/11 | 04/11 | | |
NCT00488670: Escitalopram and Depression in Elderly Alzheimer's Patients |
|
|
| Terminated | 3 | 50 | Canada | Escitalopram | University of British Columbia | Depressive Disorder | 06/11 | 06/11 | | |
NCT01401595: Brain Imaging and Treatment Studies of the Night Eating Syndrome |
|
|
| Completed | 3 | 87 | US | escitalopram oxalate, Lexapro | University of Pennsylvania, Forest Laboratories | Night Eating Syndrome | 09/11 | 09/11 | | |
ACES 263, NCT01111565 / 2010-018859-97: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) |
|
|
| Terminated | 3 | 137 | Europe, Canada, US, RoW | Escitalopram, Aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
ACES 255, NCT01111539 / 2010-018796-21: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) |
|
|
| Terminated | 3 | 211 | Europe, US, RoW | Escitalopram, Aripiprazole, Blinded capsule | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
ACES 256, NCT01111552 / 2010-018858-12: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) |
|
|
| Terminated | 3 | 237 | Europe, US, RoW | Escitalopram, Aripiprazole, OPC-14597, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
| Terminated | 3 | 173 | NA | Aripiprazole, OPC-14597, Escitalopram | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
NCT00953108 / 2009-011911-19: Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients |
|
|
| Completed | 3 | 60 | Europe | quetiapine, escitalopram | Ludwig-Maximilians - University of Munich | Major Depression | 02/12 | 02/12 | | |
NCT00239954: Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder |
|
|
| Unknown status | 3 | | US | Escitalopram | Pharmacology Research Institute | Major Depressive Disorder | | | | |
2011-005320-17: Effects of agomelatine on emotional experiences in depressed adults patients as compared to escitalopram |
|
|
| Ongoing | 3 | 500 | Europe | S20098, S20098, Capsule, VALDOXAN, SEROPLEX, CIPRALEX | Institut de Recherches Internationales Servier, SRDL, Servier Research and Develpment | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT01363310: The Quietude Study: Quetiapine Use for Agitated Depression |
|
|
| Terminated | 3 | 250 | Canada | Quetiapine XR, Seroquel XR, Escitalopram | Physicians Research And Education Network | Depression With Prominent Agitation | 01/13 | 02/13 | | |
NCT00149799: Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder |
|
|
| Completed | 3 | 100 | US | Escitalopram, Lexapro, Placebo | Massachusetts General Hospital, National Institute of Mental Health (NIMH), Rhode Island Hospital | Anxiety Disorders, Somatoform Disorders | 03/13 | 03/13 | | |
| Completed | 3 | 38 | Europe | Escitalopram, Placebo | Gustave Roussy, Cancer Campus, Grand Paris | ENT Cancer | 03/13 | 03/13 | | |
2010-023576-10: Comparison of Agomelatine (25 mg/day, adjustement to 50 mg/day) with Escitalopram (10mg/day, adjustement to 20 mg/day) on general interest in outpatients with Major Depressive Disorder over 12 weeks of treatment |
|
|
| Completed | 3 | 300 | Europe | S20098, S20098, Film-coated tablet, VALDOXAN, SEROPLEX, CIPRALEX | Institut de Recherches Internationales Servier, ADIR | Major Depressive Disorder, Depression - Psychiatry, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT01364649: Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction |
|
|
| Completed | 3 | 447 | US, Canada | Vortioxetine, Lu AA21004, Escitalopram, Lexapro, Placebo | Takeda | Treatment Outcome | 12/13 | 12/13 | | |
2004-004625-96: A naturalistic study of the efficacy and safety of escitalopram in treatment resistant depression. |
|
|
| Completed | 3 | 700 | Europe | Escitalopram, Venlafaxin, Lu 26-054, Capsule*, Capsule, hard, Cipralex, Efectin | Group for the Study of Resistant Depression (GSRD), Head: Prof. Julien Mendlewicz | The screening assessment consists of a consecutive recruitment of depressed pat. adequately treated for their current depressive episode. 2. Pat. who failed to respond to a well-conducted treatment with an antidepressant and for whom the investigator considers switching to venlafaxine, will start this treatment period.3. Pat. considered as non responders at the end of the the “Venlafaxine treatmentâ€, will be included in a 6 week prospective treatment with Escit.. | | | | |
2004-000990-78: A Double-Blind, Multicentre, Randomised, Parallel-group, Placebo-controlled Study Assessing the Efficacy and Safety of Escitalopram in Post-Myocardial Infarction Patients Suffering from Depressive Symptoms. |
|
|
| Completed | 3 | 48 | Europe | Cipralex, Lu 26-054, Cipralex, Cipralex | H. Lundbeck A/S, H. Lundbeck A/S, Lundbeck Austria GmbH | Depressive symptoms in post myocardial infarction patients | | 06/05 | | |
2005-001411-22: Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study |
|
|
| | 3 | 20 | Europe | Cipralex, | University School of Medicine Hannover (MHH), represented by the chairmanship | Obsessive compulsive disorder | | 07/13 | | |
2006-004716-48: Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder.A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months. |
|
|
| | 3 | 50 | Europe | S20098, S20098, CIPRALEX, SEROPLEX, CIPRALEX, SEROPLEX | Institut de Recherches Internationales Servier, Servier Research and Development Limited | Major Depressive Disorder | | 10/08 | | |
2006-006540-54: Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day).Twelve-week treatment plus double-blind extension for 12 weeks. |
|
|
| Ongoing | 3 | 100 | Europe | S20098, S20098, CIPRALEX, CIPRALEX | Institut de Recherches Internationales Servier, Servier Research and Development Limited | Major Depressive Disorder | | | | |
2007-001540-45: Triiodothyronine as an adjunct to accelerate the antidepressant effects of the selective serotonin reuptake inhibitor (SSRI) escitalopram |
|
|
| Completed | 3 | 60 | Europe | THYBON, Cipralex 10 mg, Thybon 20 Henning; Thybon 100 Henning, Cipralex 10 mg, Thybon 20 Henning; Thybon 100 Henning, Cipralex 10 mg | Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine | Depressive episode | | 10/12 | | |
2007-004009-93: Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson\'s disease and effectiveness of escitalopram Prevalenza di depressione, disturbi d\'ansia e di controllo degli impulsi in soggetti con malattia di Parkinson ed efficacia di escitalopram |
|
|
| Completed | 3 | 210 | Europe | CIPRALEX, CIPRALEX | LUNDBECK ITALIA | Depression, anxiety and ICD disturbo depressivo, d\'ansia e disturbo di controllo degli impulsi | | | | |
2009-013789-17: Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder. |
|
|
| Completed | 3 | 80 | Europe | S20098, S20098, VALDOXAN, CIPRALEX, VALDOXAN, CIPRALEX | Institut de Recherches Internationales Servier, ADIR, | Generalized anxiety disorder | | 07/11 | | |
2012-003699-37: Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in non-depressed out-patients with severe Generalized Anxiety Disorder. A 12-week randomised, double-blind, versus escitalopram, 2-arm parallel groups, international multicenter study with a 9-month extension period Hodnocení účinnosti a bezpečnosti agomelatinu (25 mg denně s možností zaslepeného zvýšení na 50 mg denně) oproti escitalopramu (10 mg denně s možností zaslepeného zvýšení na 20 mg denně) po dobu 12 týdnů u ambulantních pacientů s těžkou generalizovanou úzkostnou poruchou bez deprese. 12týdenní, randomizovaná, dvojitě zaslepená, mezinárodní, multicentrická studie s escitalopramem jako srovnávacím přípravkem, se dvěma paralelními skupinami a s možností prodloužení o 9měsíční období. |
|
|
| Completed | 3 | 90 | Europe | S20098, S20098, VALDOXAN, SEROPLEX, CIPRALEX, VALDOXAN, SEROPLEX, CIPRALEX | Institut de Recherches Internationales Servier, ADIR | Generalized Anxiety Disorder | | 02/15 | | |
2012-005612-26: Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks. |
|
|
| Ongoing | 3 | 60 | Europe | S01574, S01574, Stablon, Seroplex, Cipralex, Stablon, Seroplex, Cipralex | Institut de Recherches Internationales Servier, ADIR | Major Depressive Disorder | | | | |
NCT02272517 / 2014-000231-16: Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder |
|
|
| Completed | 3 | 101 | Europe, RoW | Vortioxetine 10-20 mg, Brintellix®, Lu AA21004, Escitalopram 10-20 mg | H. Lundbeck A/S | Major Depressive Disorder | 03/16 | 03/16 | | |
NCT01894815: Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial |
|
|
| Completed | 3 | 245 | RoW | Escitalopram oxalate, Reconter, transcranial direct current stimulation, tDCS - Soterix Medical Device for Clinical Trials, Sham tDCS + Placebo Pill | University of Sao Paulo, Fundação de Amparo à Pesquisa do Estado de São Paulo, Brain & Behavior Research Foundation | Major Depressive Disorder, Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified | 07/16 | 11/16 | | |
NCT02191397: Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder |
|
|
| Completed | 3 | 534 | RoW | Bupropion, Bupropion Matching Placebo, Escitalopram, Escitalopram Matching Placebo | GlaxoSmithKline | Depressive Disorder, Major | 10/16 | 10/16 | | |
| Completed | 3 | 211 | Canada | escitalopram, Cipralex, aripiprazole, Abilify | University Health Network, Toronto, University of Toronto, University of Calgary, University of British Columbia, McGill University, Queen's University, Centre for Addiction and Mental Health, McMaster University | Major Depressive Disorder | 01/17 | 01/17 | | |
2013-004881-33: Multicentre trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescents Groß an gelegte, einfache offene klinische Studie mit mehreren teilnehmenden Prüfzentren zur Anwendung von Antidepressiva und Neuroleptika (mit /ohne Zulassung) |
|
|
| Ongoing | 3 | 1000 | Europe | Tablet, Abilify, Zyprexa, Leponex, Seroquel, Risperdal, Zeldox, Melneurin, Dipiperon, Saroten, Cipramil, Anafranil, Aponal, Cymbalta, Cipralex, Fluctin, Fevarin, Tofranil, Ludiomil, Remergil, Nortrilen, Paroxat, Zoloft, Stangyl, Trevilor | Universitätsklinikum Würzburg, Kompetenznetz TDM-KJP e.V., BfArM | therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT01522092: Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations |
|
|
| Withdrawn | 3 | 0 | Europe | escitalopram, Cipralex | Hull University Teaching Hospitals NHS Trust | Anxiety, COPD | | | | |
| Completed | 3 | 2944 | Canada, US, Europe, RoW | OPC-34712, Escitalopram, Lexapro, Fluoxetine, Prozac, Paroxetine CR, Paxil CR, Sertraline, Zoloft, Duloxetine, Cymbalta, Venlafaxine XR, Effexor XR | Otsuka Pharmaceutical Development & Commercialization, Inc. | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | 04/17 | 05/17 | | |
|
TRANSFORM-2, NCT02418585 / 2014-004585-22: A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 236 | Europe, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 06/17 | 11/17 | | |
|
NCT02374567: Pharmacovigilance in Gerontopsychiatric Patients |
|
|
| Terminated | 3 | 407 | Europe | Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Valproic Acid, Lamotrigine, Topiramate, Gabapentin, Levetiracetam, Pregabalin, Lacosamide, Clonazepam, Biperiden, Levomepromazine, Fluphenazine, Perphenazine, Perazine, Thioridazine, Haloperidol, Melperone, Pipamperone, Bromperidol, Benperidol, Sertindole, Ziprasidone, Flupentixol, Chlorprothixene, Zuclopenthixol, Fluspirilene, Pimozide, Clozapine, Olanzapine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Prothipendyl, Risperidone, Aripiprazole, Paliperidone, Diazepam, Oxazepam, Lorazepam, Bromazepam, Clobazam, Alprazolam, Hydroxyzine, Buspirone, Chloral Hydrate, Flurazepam, Nitrazepam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Zopiclone, Zolpidem, Zaleplon, Melatonin, Clomethiazole, Diphenhydramine, Promethazine, Imipramine, Clomipramine, Opipramol, Trimipramine, Amitriptyline, Nortriptyline, Doxepin, Maprotiline, Amitriptyline oxide, Fluoxetine, Citalopram, Paroxetine, Sertraline, Fluvoxamine, Escitalopram, Tranylcypromine, Moclobemide, Mianserin, Trazodone, Mirtazapine, Bupropion, Venlafaxine, Reboxetine, Duloxetine, Agomelatine, Pyritinol, Piracetam, Donepezil, Rivastigmine, Galantamine, Memantine, Nicergoline, Acamprosate, Lithium | Hannover Medical School | Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders | 06/17 | 06/17 | | |
TRANSFORM-3, NCT02422186 / 2014-004588-19: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 139 | Europe, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 08/17 | 08/17 | | |
|
| Completed | 3 | 802 | Europe, US, RoW | Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 10/17 | 10/17 | | |
| Completed | 3 | 719 | Europe, Canada, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 02/18 | 02/18 | | |
TRANSFORM-1, NCT02417064 / 2014-004584-20: A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 346 | Europe, Canada, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 02/18 | 02/18 | | |
|
| Completed | 3 | 71 | RoW | Escitalopram, Lexapro, Placebo | Chinese University of Hong Kong | Dyspepsia, Anxiety, Depression | 12/18 | 01/19 | | |
NCT00958633: Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. |
|
|
| Completed | 3 | 178 | Canada | Escitalopram, Lexapro/Cipralex, Wellbutrin XL, Wellbutrin | University of British Columbia, Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, Lundbeck Canada Inc., Lupin Limited | Bipolar I Disorder | 03/20 | 05/20 | | |
NCT03434041: A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 252 | US, RoW | Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 04/21 | 04/21 | | |
NCT03852160: A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression |
|
|
| Withdrawn | 3 | 0 | NA | Esketamine 28 mg, JNJ-54135419, Esketamine 56 mg, Esketamine 84 mg, Placebo, Escitalopram, Sertraline, Duloxetine, Mirtazapine, Agomelatine, Bupropion, Trazodone Prolonged Release | Janssen-Cilag International NV | Depressive Disorder, Treatment-Resistant | 07/21 | 07/21 | | |
NCT04476030: A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 440 | US | SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine | Biogen | Depressive Disorder, Major | 10/21 | 12/21 | | |
|
|
| Terminated | 3 | 1 | Europe | Mirtazapine, Escitalopram | Hospices Civils de Lyon | Cancer, Neoplasms, Neoplasm Metastasis | 12/21 | 12/21 | | |
| Terminated | 3 | 111 | RoW | Escitalopram 10mg, LABCAT TCJUSS, LABCAT TCJUSS Placebo, Escitalopram Placebo | Laboratório Catarinense SA, Universidade Federal do Ceara, Financiadora de Estudos e Projetos | Depression | 06/22 | 06/22 | | |
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 1149 | US | Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 07/22 | 07/22 | | |
NCT05950061: Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder |
|
|
| Completed | 3 | 744 | RoW | Sertraline, Sertraline pill, Escitalopram, Escitalopram pill | KRL Hospital, Islamabad, Khyber Medical College, Peshawar, Quaid-e-Azam Medical College, Dow University of Health Sciences | Major Depressive Disorder | 10/22 | 02/23 | | |
NCT04162522: Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study |
|
|
| Completed | 3 | 1 | Canada | Escitalopram, Cipralex, Brexpiprazole, Rexulti | University Health Network, Toronto, Unity Health Toronto, Baycrest, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University | Major Depressive Disorder | 12/22 | 12/22 | | |
| Completed | 3 | 52 | Europe | Nortriptyline, Nortriptyline 25mg, Escitalopram, Escitalopram 5mg, Placebo, Placebo oral tablet | University College, London, London North West Healthcare NHS Trust, King's College London, University Hospital Plymouth NHS Trust, NHS Lothian | Depression, Parkinson Disease | 01/23 | 04/23 | | |
NCT05480878: Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 90 | RoW | Placebo, Nitazoxanide 500Mg Oral Tablet, Escitalopram 10mg | Tanta University | Rheumatoid Arthritis | 03/23 | 04/23 | | |
NCT06025474: Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome |
|
|
| Recruiting | 3 | 203 | Europe | Vortioxetine 20Mg Tab, Brintellix, Paroxetine 20 Mg Oral Tablet, Sertraline 50 MG, Citalopram 20mg, Escitalopram 10mg, Duloxetine 60 MG, Pregabalin 75mg | Federico II University | Burning Mouth Syndrome | 10/23 | 07/24 | | |
IPT, NCT04973930: Feasibility Trial of Tele- and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 20 | US | Interpersonal Psychotherapy, IPT, Venlafaxine HCl ER, Escitalopram Oral Tablet | New York State Psychiatric Institute, Columbia University | Major Depressive Disorder, Breast Cancer, Venlafaxine | 12/24 | 12/24 | | |
| Active, not recruiting | 3 | 187 | Canada, US | Escitalopram, Lexapro, Placebo, non-applicable | JHSPH Center for Clinical Trials, National Institute on Aging (NIA) | Dementia | 03/24 | 05/25 | | |
INTENSIFY BD, NCT05973786: The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. |
|
|
| Recruiting | 3 | 418 | Europe | Escitalopram, ATC code: N06AB10, Sertraline, ATC code: N06AB06, Venlafaxine, ATC code: N06AX16, Lithium, ATC code: N05AN01, Valproate acid, ATC code: N03AG01, Quetiapine, ATC code: N05AH04 | Dr. Inge Winter, Universität Münster | Bipolar Depression | 06/26 | 06/26 | | |
INTENSIFY, NCT05603104: Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure |
|
|
| Not yet recruiting | 3 | 1254 | RoW | Clozapine, ATC code: N05AH02, Esketamine Nasal Product, ATC code: N06AB10, Escitalopram, Sertraline, ATC code: N06AB06, Venlafaxine, ATC code: N06AX16, Lithium, ATC code: N05AN01, Valproate acid, ATC code: N03AG01, Quetiapine, ATC code: N05AH04, Second-line Antidepressants, Second-line Antipsychotics, Ketamine Hydrochloride, N01AX03, Esketamine hydrochloride, N015X14 | Dr. Inge Winter, Universität Münster | Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression | 06/26 | 06/26 | | |
NCT00121069: Study of Escitalopram in the Treatment of Specific Phobia |
|
|
| Completed | 2/3 | 12 | US | Escitalopram | Connor, Kathryn M., M.D., Forest Laboratories | Phobic Disorders | | 09/04 | | |
NCT00080158: Treatment of Adolescent Suicide Attempters (TASA) |
|
|
| Completed | 2/3 | 120 | US | fluoxetine, sertraline, citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, lithium, Cognitive Behavioral Therapy | New York State Psychiatric Institute, National Institute of Mental Health (NIMH) | Depression, Suicide, Attempted | | 06/07 | | |
NCT00215228: Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression |
|
|
| Completed | 2/3 | 26 | US | duloxetine vs. escitalopram | Duke University, Forest Laboratories | Major Depressive Disorder | | 08/07 | | |
NCT00481325: Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder |
|
|
| Completed | 2/3 | 260 | US | pexacerfont, (BMS-562086), escitalopram, placebo | Bristol-Myers Squibb | Generalized Anxiety Disorder | 03/08 | 03/08 | | |
NCT00133276: Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment |
|
|
| Completed | 2/3 | 80 | Europe | Escitalopram, Lexapro, Placebo | Foundation for Liver Research | Hepatitis C | 06/08 | 12/09 | | |
NCT00655057: Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression |
|
|
| Completed | 2/3 | 66 | US | S-citalopram, Cognitive behavioral therapy (CBT), TRODAT-1 single photon emission computed tomographic (SPECT) imaging | University of Pennsylvania, National Institute of Mental Health (NIMH) | Depression | 08/09 | 12/09 | | |
NCT01876823: Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment |
|
|
| Completed | 2/3 | 60 | US | es-citalopram, Lexapro, Memantine, Namenda | New York State Psychiatric Institute | Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease | 03/10 | 03/10 | | |
